Antistaphylococcal Activity of TD-1792, a Multivalent Glycopeptide-Cephalosporin Antibiotic

Blais, Johanne; Lewis, Stacey R.; Krause, Kevin M.; Benton, Bret M.

doi:10.1128/aac.05532-11

Cited by 41 publications

(29 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…70 This compound is highly potent against MRSA and VRSA in that it simultaneously inhibits the activity of PBPs and interferes with PG precursor binding. 71 …”

mentioning

confidence: 99%

One ring to rule them all: Current trends in combating bacterial resistance to the β‐lactams

2016

View full text Add to dashboard Cite

From humble beginnings of a contaminated petri dish, b-lactam antibiotics have distinguished themselves among some of the most powerful drugs in human history. The devastating effects of antibiotic resistance have nevertheless led to an "arms race" with disquieting prospects. The emergence of multidrug resistant bacteria threatens an ever-dwindling antibiotic arsenal, calling for new discovery, rediscovery, and innovation in b-lactam research. Here the current state of b-lactam antibiotics from a structural perspective was reviewed.

show abstract

“…70 This compound is highly potent against MRSA and VRSA in that it simultaneously inhibits the activity of PBPs and interferes with PG precursor binding. 71 …”

mentioning

confidence: 99%

One ring to rule them all: Current trends in combating bacterial resistance to the β‐lactams

2016

View full text Add to dashboard Cite

show abstract

“…TD-1792 was evaluated in a phase II clinical study for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria, including resistant strains such as MRSA. Phase III clinical study was recently completed and clinical efficacy and safety were evaluated within an expanded patient population [40,41,42,43]. …”

Section: Antibacterial Agents and Non-antibiotic Therapeutics In Cmentioning

confidence: 99%

Advances in MRSA drug discovery: where are we and where do we need to be?

Kurosu¹,

Siricilla²,

Mitachi³

2013

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Introduction Methicillin-resistant Staphylococcus aureus (MRSA) have been on the increase during the past decade, due to the steady growth of the elderly and immunocompromised patients, and the emergence of multi-drug-resistant (MDR) bacterial strains. Although, only a limited number of anti-MRSA drugs are available, a number of different combination antimicrobial drug regimens have been used to treat serious MRSA infections. Thus, addition of several new antistaphylococcal drugs into clinical practice should broaden therapeutic options. Because MRSA is one of the most common and problematic bacteria associated with increasing antimicrobial resistance, continuous efforts on discovery of lead compounds as well as development of alternative therapies and faster diagnostics to ensure effective antistaphylococcal therapy are required. Areas covered This article summarizes the FDA approved drugs to treat MRSA infections, the drugs in clinical trials, and the drug leads for MRSA and related Gram-positive bacterial infections. In addition, the mode of action of antistaphylococcal molecules and resistant mechanisms of some molecules are briefly discussed. Expert opinion The number of pipeline drugs presently undergoing clinical trials is not particularly encouraging. There are limited and rather expensive therapeutic options for the infections by MRSA in the critically ill. This review article provides an update on antistaphylococcal drugs in clinical trials and antibacterial molecules effective against Gram-positive bacteria including MRSA. The structural and biological information of antibacterials summarized here are very useful for designing drug leads to develop into new anti-MRSA drugs.

show abstract

“…It possesses potent activity against Grampositive bacteria, including methicillin-sensitive S. aureus (MSSA), MRSA and vancomycin-intermediate S. aureus (VISA). The unique chemical structure of TD-1792 causes bacterial susceptibility and probably will result in slower development of resistance [19].…”

Section: Cephalosporinsmentioning

confidence: 99%

New perspectives on antibacterial drug research

2013

View full text Add to dashboard Cite

Bacterial resistance to commonly used antibiotics is constantly increasing. Bacteria particularly dangerous for human life are methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and fluoroquinolone-resistant Pseudomonas aeruginosa. Hence, there is an incessant need for developing compounds with new modes of action and seeking alternate drug targets. In this review, the authors discuss the current situation of antibacterial medicines and present data on new antibiotic targets. Moreover, alternatives to antibiotics, such as bacteriophages, antimicrobial peptides and monoclonal antibodies, are presented. The authors also draw attention to the valuable features of natural sources in developing antibacterial compounds. The need to prevent and control infections as well as the reasonable use of currently available antibiotics is also emphasized.

show abstract

Antistaphylococcal Activity of TD-1792, a Multivalent Glycopeptide-Cephalosporin Antibiotic

Cited by 41 publications

References 8 publications

One ring to rule them all: Current trends in combating bacterial resistance to the β‐lactams

One ring to rule them all: Current trends in combating bacterial resistance to the β‐lactams

Advances in MRSA drug discovery: where are we and where do we need to be?

New perspectives on antibacterial drug research

Contact Info

Product

Resources

About